Recent advances in the treatment of myelodysplastic syndromes;Avancées dans la prise en charge des syndromes myélodysplasiques

Revue de Medecine Interne

Volumn 27, Issue 8, 2006, Pages 600-609

  Gelsi Boyer, V ^a,c   Vey, N ^b,c  

^a Département de BioPathologie   (France)

^b Service d'Hématologie   (France)

^c INSTITUT PAOLI CALMETTES   (France)

Author keywords

Diagnosis; Myelodysplastic syndromes; Physiopathology; Treatment

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BORTEZOMIB; CYCLOSPORIN A; CYTOTOXIC AGENT; ERYTHROPOIETIN; EVEROLIMUS; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAPAMYCIN; THALIDOMIDE; THYMOCYTE ANTIBODY; TIPIFARNIB; TUMOR NECROSIS FACTOR ANTIBODY; VALPROIC ACID; VASCULOTROPIN INHIBITOR; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANGIOGENESIS; APOPTOSIS; CANCER CHEMOTHERAPY; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE COURSE; EPIGENETICS; GENETIC REGULATION; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HUMAN; MICROENVIRONMENT; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PATHOPHYSIOLOGY; PROGNOSIS; SHORT SURVEY; SIGNAL TRANSDUCTION; ALLOTRANSPLANTATION; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOGENETICS; GENETICS; REMISSION; REVIEW; STEM CELL TRANSPLANTATION;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS; CYTOGENETICS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 33747245028     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2006.02.008     Document Type: Short Survey

References (57)

1. Rosenfeld C., and List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 14 1 (2000) 2-8
2. Gallagher A., Darley R.L., and Padua R. The molecular basis of myelodysplastic syndromes. Haematologica 82 2 (1997) 191-204
3. Fenaux P. Myelodysplastic syndromes: From pathogenesis and prognosis to treatment. Semin. Hematol. 41 2 (2004) 6-12 (Suppl 4)
4. Mufti G.J., and Galton D.A. Myelodysplastic syndromes: natural history and features of prognostic importance. Clin. Haematol. 15 4 (1986) 953-971
5. Faderl S., and Kantarjian H.M. Novel therapies for myelodysplastic syndromes. Cancer 101 2 (2004) 226-241
6. Mufti G., List A.F., Gore S.D., and Ho A.Y. Myelodysplastic syndrome. Hematology (Am. Soc. Hematol. Educ. Program) (2003) 176-199
7. Schouten H.C., Vellenga E., van Rhenen D.J., de Wolf J.T., Coppens P.J., and Blijham G.H. Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia 5 5 (1991) 432-436
8. Jacobs A., Janowska-Wieczorek A., Caro J., Bowen D.T., and Lewis T. Circulating erythropoietin in patients with myelodysplastic syndromes. Br. J. Haematol. 73 1 (1989) 36-39
9. Merchav S., Wagemaker G., Souza L.M., and Tatarsky I. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors. Leukemia 5 4 (1991) 340-346
10. Claessens Y.E., Bouscary D., Dupont J.M., Picard F., Melle J., Gisselbrecht S., et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 99 5 (2002) 1594-1601
11. Parker J.E., Mufti G.J., Rasool F., Mijovic A., Devereux S., and Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 96 12 (2000) 3932-3938
12. Hamblin T.J. Immunological abnormalities in myelodysplastic syndromes. Semin. Hematol. 33 2 (1996) 150-162
13. Hellstrom-Lindberg E., Willman C., Barrett A.J., and Saunthararajah Y. Achievements in Understanding and Treatment of Myelodysplastic Syndromes. Hematology (Am. Soc. Hematol. Educ. Program) (2000) 110-132
14. Bellamy W.T., Richter L., Sirjani D., Roxas C., Glinsmann-Gibson B., Frutiger Y., et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97 5 (2001) 1427-1434
15. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 6 (1997) 2079-2088
16. Fenaux P. Myelodysplastic syndromes. Hematol. Cell Ther. 38 5 (1996) 363-380
17. Steensma D.P., and List A.F. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin. Proc. 80 5 (2005) 681-698
18. Claus R., and Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene 22 42 (2003) 6489-6496
19. Quesnel B., Guillerm G., Vereecque R., Wattel E., Preudhomme C., Bauters F., et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91 8 (1998) 2985-2990
20. Kuendgen A., Strupp C., Aivado M., Bernhardt A., Hildebrandt B., Haas R., et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104 5 (2004) 1266-1269
21. Martinez-Ramirez A., Urioste M., Melchor L., Blesa D., Valle L., de Andres S.A., et al. Analysis of myelodysplastic syndromes with complex karyotypes by high-resolution comparative genomic hybridization and subtelomeric CGH array. Genes Chromosomes Cancer 42 3 (2005) 287-298
22. Ishkanian A.S., Malloff C.A., Watson S.K., DeLeeuw R.J., Chi B., Coe B.P., et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat. Genet. 36 3 (2004) 299-303
23. Miyazato A., Ueno S., Ohmine K., Ueda M., Yoshida K., Yamashita Y., et al. Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 98 2 (2001) 422-427
24. Pellagatti A., Fidler C., Wainscoat J.S., and Boultwood J. Gene expression profiling in the myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 10 4 (2005) 281-287
25. Tsutsumi C., Ueda M., Miyazaki Y., Yamashita Y., Choi Y.L., Ota J., et al. DNA microarray analysis of dysplastic morphology associated with acute myeloid leukemia. Exp. Hematol. 32 9 (2004) 828-835
26. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 7 (2002) 2292-2302
27. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann. Oncol. 10 12 (1999) 1419-1432
28. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51 2 (1982) 189-199
29. Germing U., Gattermann N., Strupp C., Aivado M., and Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk. Res. 24 12 (2000) 983-992
30. Pierre R.V., Catovsky D., Mufti G.J., Swansbury G.J., Mecucci C., Dewald G.W., et al. Clinical-cytogenetic correlations in myelodysplasia (preleukemia). Cancer Genet. Cytogenet. 40 2 (1989) 149-161
31. Steensma D.P., Dewald G.W., Hodnefield J.M., Tefferi A., and Hanson C.A. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?. Leuk. Res. 27 3 (2003) 235-242
32. Fenaux P., Preudhomme C., Lai J.L., Morel P., Beuscart R., and Bauters F. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases. Br. J. Haematol. 73 1 (1989) 61-67
33. List A., Kurtin S., Roe D.J., Buresh A., Mahadevan D., Fuchs D., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 352 6 (2005) 549-557
34. Aguayo A., Kantarjian H.M., Estey E.H., Giles F.J., Verstovsek S., Manshouri T., et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 95 9 (2002) 1923-1930
35. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96 12 (2000) 3671-3674
36. Mantovani L., Lentini G., Hentschel B., Wickramanayake P.D., Loeffler M., Diehl V., et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br. J. Haematol. 109 2 (2000) 367-375
37. Silva M., Grillot D., Benito A., Richard C., Nunez G., and Fernandez-Luna J.L. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 88 5 (1996) 1576-1582
38. Schmidt-Mende J., Tehranchi R., Forsblom A.M., Joseph B., Christensson B., Fadeel B., et al. Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia 15 5 (2001) 742-751
39. Casadevall N., Durieux P., Dubois S., Hemery F., Lepage E., Quarre M.C., et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104 2 (2004) 321-327
40. Hellstrom-Lindberg E., Ahlgren T., Beguin Y., Carlsson M., Carneskog J., Dahl I.M., et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92 1 (1998) 68-75
41. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., Ahlgren T., Dahl I.M., Dybedal I., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br. J. Haematol. 120 6 (2003) 1037-1046
42. Beran M., Shen Y., Kantarjian H., O'Brien S., Koller C.A., Giles F.J., et al. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 92 8 (2001) 1999-2015
43. de Witte T., Suciu S., Peetermans M., Fenaux P., Strijckmans P., Hayat M., et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 9 11 (1995) 1805-1811
44. Fenaux P., Morel P., Rose C., Lai J.L., Jouet J.P., and Bauters F. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br. J. Haematol. 77 4 (1991) 497-501
45. Estey E., Thall P., Beran M., Kantarjian H., Pierce S., and Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 90 8 (1997) 2969-2977
46. de Witte T., Hermans J., Vossen J., Bacigalupo A., Meloni G., Jacobsen N., et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br. J. Haematol. 110 3 (2000) 620-630
47. Appelbaum F.R., and Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 12 Suppl 1 (1998) S25-S29
48. Cutler C.S., Lee S.J., Greenberg P., Deeg H.J., Perez W.S., Anasetti C., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104 2 (2004) 579-585
49. Mohty M., Faucher C., and Blaise D. Immunotherapy with allogeneic haematopoietic stem cell transplantation: current status and perspectives. Rev. Med. Interne 26 1 (2005) 33-40
50. Molldrem J.J., Leifer E., Bahceci E., Saunthararajah Y., Rivera M., Dunbar C., et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann. Intern. Med. 137 3 (2002) 156-163
51. Saunthararajah Y., Nakamura R., Wesley R., Wang Q.J., and Barrett A.J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 102 8 (2003) 3025-3027
52. Daskalakis M., Nguyen T.T., Nguyen C., Guldberg P., Kohler G., Wijermans P., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 100 8 (2002) 2957-2964
53. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20 10 (2002) 2429-2440
54. Lubbert M., Wijermans P., Kunzmann R., Verhoef G., Bosly A., Ravoet C., et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br. J. Haematol. 114 2 (2001) 349-357
55. Raza A., Meyer P., Dutt D., Zorat F., Lisak L., Nascimben F., et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98 4 (2001) 958-965
56. Kurzrock R., Albitar M., Cortes J.E., Estey E.H., Faderl S.H., Garcia-Manero G., et al. Phase II study of R115777, a farnesyl-transferase inhibitor, in myelodysplastic syndrome. J. Clin. Oncol. 22 7 (2004) 1287-1292
57. Vey N, Dreyfus F, Guerci A, Fenaux P, Dombret H, Burnett A, et al. Arsenic trioxide in patients with Myelodysplastic Syndromes: a phase I/II multicenter study. J. Clin. Oncol. 2006.